Aspergillus fumigatus Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines or inconsistent antibody performance in Aspergillus fumigatus studies? Creative Biolabs' A. fumigatus specific Neutra™ antibody products leverage advanced protein engineering and validated high-affinity designs to accelerate therapeutic discovery, streamline diagnostics, and deliver reproducible results in fungal pathogenesis research.

Introduction to Aspergillus fumigatus

Aspergillus fumigatus (A. fumigatus) is a ubiquitous, saprophytic fungus responsible for life-threatening invasive aspergillosis in immunocompromised individuals. Its airborne conidia, 2–3 µm in diameter, evade mucociliary clearance and germinate into hyphae under favorable host conditions. As a leading opportunistic pathogen, A. fumigatus exhibits thermotolerance, surviving up to 55°C, and secretes virulence factors like gliotoxin and proteases, enabling tissue invasion and immune evasion.

• Structural Features

A. fumigatus conidia and hyphae are protected by a cell wall composed of chitin, β-glucans, and galactomannan. Surface antigens, including RodA hydrophobin and galactomannan, mediate host adhesion and immune recognition. The cell wall's dynamic architecture—critical for fungal survival—serves as a primary target for therapeutic antibodies. Structural studies reveal epitope conservation in antigens such as Asp f1 (a ribotoxin) and Asp f3 (a peroxisomal protein), enabling precise antibody development.

• Host-Pathogen Signaling Pathways

A. fumigatus activates Toll-like receptors (TLRs) and C-type lectin receptors (e.g., Dectin-1) on immune cells, triggering NF-κB and MAPK pathways to drive pro-inflammatory cytokine production. Simultaneously, the fungus evades phagocytosis via melanin-coated conidia and suppresses reactive oxygen species (ROS) through catalases. Neutralizing antibodies targeting immunodominant antigens disrupt these interactions, restoring immune-mediated clearance.

Fig.1 Receptor-mediated signaling in A. fumigatus.¹

• Associated Diseases

Invasive aspergillosis, allergic bronchopulmonary aspergillosis (ABPA), and chronic pulmonary aspergillosis are major clinical manifestations. High-risk populations include transplant recipients, leukemia patients, and those with chronic obstructive pulmonary disease (COPD). Mortality rates exceed 50% in invasive cases due to delayed diagnosis and limited antifungal efficacy, underscoring the need for antibody-based interventions.

Applications of Anti-A. fumigatus Neutralizing Antibodies

• Diagnostic Advancement

Anti-A. fumigatus antibodies are pivotal in developing rapid diagnostic assays. Galactomannan-specific IgM/IgG pairs enable early detection of invasive aspergillosis in serum and bronchoalveolar lavage samples, reducing reliance on culture-based methods. High-throughput ELISA kits incorporating these antibodies achieve diagnostic specificity >90%, critical for immunocompromised patients.

• Therapeutic Development

Neutralizing monoclonal antibodies (mAbs) targeting Asp f3 or β-glucan exhibit potent fungistatic effects. In murine models, anti-β-glucan mAbs enhance neutrophil-mediated hyphal damage, reducing fungal burden by 80%. Clinical-stage candidates are being evaluated for adjunctive therapy alongside antifungals, showing promise in reducing mortality rates.

• Preventive Strategies

Prophylactic administration of anti-RodA antibodies in high-risk populations blocks conidial adherence to lung tissue, preventing germination. Passive immunization studies demonstrate >70% efficacy in preventing invasive disease in immunosuppressed hosts, offering a novel approach to outbreak control.

• Research Tool Optimization

Antibodies enable precise tracking of fungal load and immune responses in vivo. Applications include flow cytometry for immune cell profiling, immunohistochemistry to visualize hyphal invasion, and functional assays quantifying phagocytosis efficiency.

Our Anti-A. fumigatus Antibodies

Creative Biolabs' antibodies target A. fumigatus conserved virulence factors and surface antigens with high specificity:

- Anti-Asp f1 IgG: Neutralizes ribotoxic activity, blocking host cell apoptosis and cytokine dysregulation.

- Anti-galactomannan IgM/IgG: Detects circulating biomarkers for early invasive aspergillosis diagnosis.

- Anti-RodA monoclonal antibodies: Prevent conidial adhesion to pulmonary epithelial cells, reducing fungal colonization.

Validated in ELISA, immunofluorescence, and neutralization assays, these antibodies demonstrate >95% sensitivity in preclinical models, enabling reliable translational research.

Creative Biolabs' A. fumigatus specific Neutra™ antibody products combine cutting-edge specificity with robust validation, empowering researchers to overcome challenges in antifungal drug development and diagnostics. Contact our team today to discuss custom antibody solutions tailored to your project needs.

REFERENCE

1. Grice, C. M., M. Bertuzzi, and E. M. Bignell. "Receptor-mediated signaling in Aspergillus fumigatus." Frontiers in microbiology 4 (2013): 26. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.3389/fmicb.2013.00026